WILLIAM S. REARDON - Corporate Board Profile

abrdn Healthcare Investors

Filing Date	Source Excerpt
2010-04-27	William S. Reardon (63), Trustee, HQH and HQL; No committee memberships mentioned; Compensation not stated.
2011-06-08	Mr. Reardon's personal experience as a Life Science audit partner at PricewaterhouseCooper ("PwC"), with a broad spectrum of companies across the corporate life cycle from startup to successful product driven pharmaceutical companies, provides the Trustees of the Fund, and especially the Valuation Committee with a valuable perspective in analyzing life science company opportunities and in valuing the venture portion of the portfolio. ... He serves on the Valuation Committee of the Fund. ... Compensation Table ... William S. Reardon ... Total Compensation ... $4,400
2012-04-30	William S. Reardon, CPA: Mr. Reardon's personal experience as a Life Science audit partner at PricewaterhouseCooper ("PwC"), with a broad spectrum of companies across the corporate life cycle from startup to successful product driven pharmaceutical companies, provides the Trustees of the Fund, and especially the Valuation Committee with a valuable perspective in analyzing life science company opportunities and in valuing the venture portion of the portfolio.
2013-04-25	William S. Reardon: Mr. Reardon's personal experience as a Life Science audit partner at PricewaterhouseCoopers LLP ("PwC"), with a broad spectrum of companies across the corporate life cycle from startup to successful product driven pharmaceutical companies, provides the Trustees of the Fund, and especially the Valuation Committee, with a valuable perspective in analyzing life science company opportunities and in valuing the venture portion of the portfolio. He serves on the Valuation and Audit Committees of the Fund. ... Compensation Table For the fiscal year ended September 30, 2012 ... William S. Reardon $27,500 + $27,500 = $55,000 total compensation.
2018-04-18	William S. Reardon: Mr. Reardon's personal experience as a Life Science audit partner at PricewaterhouseCoopers LLP ("PwC"), with a broad spectrum of companies across the corporate life cycle from startup to successful product driven pharmaceutical companies, provides each Fund with a valuable perspective in analyzing life science company opportunities and in valuing the venture portion of the portfolio. He serves on the Valuation Committee and as Chair of the Audit Committee of each Fund.
2019-04-15	Mr. Reardon serves on the Valuation Committee and as Chair of the Audit Committee of each Fund... The members of each Fund's Audit Committee are Mr. Kent, Dr. Nabel, Mr. Reardon and Ms. Stebbins. Mr. Reardon is the Chairman of each Fund's Audit Committee... The members of each Fund's Valuation Committee are Mr. Kent, Dr. Omstead, Mr. Pohotsky and Mr. Reardon... The members of each Fund's QLCC are Dr. Jain, Mr. Pohotsky and Mr. Reardon. Mr. Reardon is the Chairman of each Fund's QLCC... For the fiscal year ended September 30, 2018... William S. Reardon... $105,750.
2020-04-14	Mr. Reardon serves on the Valuation Committee and as Chair of the Audit Committee of each Fund. ... Mr. Reardon is the Chairman of each Fund's Audit Committee. ... William S. Reardon total compensation $108,000.
2021-04-13	William S. Reardon: Mr. Reardon serves on the Valuation Committee and as Chair of the Audit Committee of each Fund. He is also a member of each Fund's Qualified Legal Compliance Committee. Compensation Table shows William S. Reardon total compensation from all funds as $107,000.

abrdn Life Sciences Investors

Filing Date	Source Excerpt
2010-04-27	William S. Reardon (63), Trustee, HQH and HQL; No committee memberships mentioned; Compensation: $0 total from both Funds.
2011-06-08	William S. Reardon, CPA: Mr. Reardon's personal experience as a Life Science audit partner at PricewaterhouseCooper ("PwC"), with a broad spectrum of companies across the corporate life cycle from startup to successful product driven pharmaceutical companies, provides the Trustees of the Fund, and especially the Valuation Committee with a valuable perspective in analyzing life science company opportunities and in valuing the venture portion of the portfolio.
2012-04-30	William S. Reardon, CPA: Mr. Reardon's personal experience as a Life Science audit partner at PricewaterhouseCooper ("PwC"), with a broad spectrum of companies across the corporate life cycle from startup to successful product driven pharmaceutical companies, provides the Trustees of the Fund, and especially the Valuation Committee, with a valuable perspective in analyzing life science company opportunities and in valuing the venture portion of the portfolio.
2013-04-25	William S. Reardon: Mr. Reardon's personal experience as a Life Science audit partner at PricewaterhouseCoopers LLP ("PwC"), with a broad spectrum of companies across the corporate life cycle from startup to successful product driven pharmaceutical companies, provides the Trustees of the Fund, and especially the Valuation Committee, with a valuable perspective in analyzing life science company opportunities and in valuing the venture portion of the portfolio. He serves on the Valuation and Audit Committees of the Fund. ... Compensation Table ... William R. Reardon ... Total Compensation from both Funds in Fund Complex Paid to Trustees $55,000.
2014-04-30	William S. Reardon (67) 2 Liberty Square, 9th Floor, Boston MA 02109 Trustee, HQH and HQL; Member of each Fund's Valuation, Audit and Qualified Legal Compliance Committees. ... The members of the Fund's Audit Committee are Mr. Reardon ... The members of the Fund's Valuation Committee are ... Mr. Reardon ... The members of the Fund's QLCC are ... Mr. Reardon ... For the fiscal year ended September 30, 2013 ... William R. Reardon, CPA ... Total Compensation from both Funds in Fund Complex Paid to Trustees $61,500.
2018-04-18	William S. Reardon: Mr. Reardon's personal experience as a Life Science audit partner at PricewaterhouseCoopers LLP provides the Fund with a valuable perspective. He serves on the Valuation Committee and as Chair of the Audit Committee of the Fund. Compensation Table: William S. Reardon $22,875; Total Compensation $90,750.
2019-04-15	Mr. Reardon serves on the Valuation Committee and as Chair of the Audit Committee of the Fund. ... For the fiscal year ended September 30, 2018, the Fund paid an annual fee of $15,000 to its Independent Trustees. The Chairman of each of the Audit Committee, the Valuation Committee and the Governance and Nominating Committee of the Fund received an additional annual fee of $2,000. The following table sets forth information regarding compensation of the Trustees and Executive Officer by the Fund for the fiscal year ended September 30, 2018: William S. Reardon: $26,625.
2020-04-14	Mr. Reardon serves on the Valuation Committee and as Chair of the Audit Committee of each Fund. ... The members of each Fund's QLCC are Dr. Jain, Mr. Pohotsky and Mr. Reardon. Mr. Reardon is the Chairman of each Fund's QLCC. ... For the fiscal year ended September 30, 2019, William S. Reardon total compensation $108,000.